Blair MacNeil: Definitely. Thanks, Nadine. Yes, you’ve largely got it right or when in terms of the dynamics in the marketplace. I would say, just in general, you can look at a year ago there was over $12 million in price compression in the market. So generally, you are seeing volumes on the Tilray side go up relative to the industry, although those segments definitely are experiencing a lot of price compression. So, from a volume standpoint, it’s really driven for us by the resurgence of our flower business. You’ll recall that I talked on earlier calls about having 46 strains in alpha and beta programs that are now commercialized that are now starting to hit the marketplace. So we expect to have a real pipeline of flower moving forward. And to Irwin’s point, flower is still the biggest segment. It’s about 40% of the total business. So we continue to have a very robust pipeline of innovation, but also of genetics for flower moving forward.
Irwin Simon: And I think the thing is — I think the big thing — I’m glad I largely got it right, Blair. But I think the big thing is, we now have the facilities to grow and taking those costs continuously out. And you heard us mention in the quarter, we’re going to run these businesses and drive them for cash. And that affected our EBITDA because we have all these fixed costs. And we will be out there looking to sell cannabis to other LPs. We’ll be out there looking to grow for others, but we are that low-cost producer there and that’s something we’re going to focus on. The other thing is we’re going to focus on innovation and what’s new. And that’s sort of what drives a lot of the growth in Canada is new innovation.
Nadine Sarwat: Got it. If I could just squeeze one more, given that you mentioned that on Germany. What are you seeing with regards to adult legalization about use legalization in particular with a focus on the EU commission when you think it could be a realistic outcome? Thank you.
Denise Faltischek: Yes. So we originally expected that we might see adult use legalization take effect as early 2024, based on where we are, I think we view that it might be later in 2024 than originally expected.
Irwin Simon: And I think if Germany could make that decision for Germany without the effects of the rest of the yield, it would happen much quicker. But as we all know, borders are open. Once it’s legal in Germany, how do you stop it from going to other borders are some of the biggest issues there. So — and listen, we have a plan in place, how do we expand our medical business. And ultimately, that is partially recreational in Israel and other countries today, even though it’s sold as medical the biggest percentage of the use is in recreational.
Nadine Sarwat: Perfect. I’ll pass it.
Operator: The next question is from the line of Andrew Carter with Stifel. Please proceed with your question.
Andrew Carter: I’ll ask one question this morning, just kind of multipart, I guess. Looking at the sequential — you’ve reiterated EBITDA guidance for the year, $70 million to $80 million. Regarding the step-up that you need to achieve that in the second half, could you walk us through the, number one, incremental cost savings I get the bad debt expense isn’t going to repeat. The Canadian adult use was shipments well below consumption give us any idea of the magnitude of what that hit was? And then incremental EBITDA from Montauk in the second half as well as kind of give us a reminder on the seasonality of beverage alcohol? Thanks.
